Literature DB >> 23356536

An update on the pharmacological management of endometriosis.

Isabelle Streuli1, Dominique de Ziegler, Pietro Santulli, Louis Marcellin, Bruno Borghese, Frédéric Batteux, Charles Chapron.   

Abstract

INTRODUCTION: Endometriosis is a common disease that causes pain symptoms and/or infertility in women in their reproductive years. The disease is characterised by the presence of endometrium-like tissue - glands and stroma - outside the uterine cavity. Different treatment options exist for endometriosis including medical and surgical treatments or a combination of the two approaches. The most commonly used medications are non-steroidal anti-inflammatory drugs, GnRH agonists, androgen derivatives such as danazol, combined oral contraceptive pills, progestogens and more recently the levonorgestrel intrauterine system. AREAS COVERED: The authors review current medical treatments used for symptomatic endometriosis and also discuss new treatment approaches. The authors conducted a literature search for randomised controlled trials related to medical treatments of endometriosis in humans, searched the Cochrane library for reviews and also searched for registered trials that have not yet been published on ClinicalTrials.gov. EXPERT OPINION: The medical treatment of endometriosis is effective at treating pain and preventing recurrence of disease after surgery. Remarkably, the oral contraceptive pill taken continuously is as effective as GnRH-a, while causing far less side-effects. Conversely, no treatment currently exists for enhancing fecundity in women whose infertility is associated with endometriosis. As all existing therapies of endometriosis are contraceptive, great efforts should be targeted at researching novel products that reduce the disease expression without shuttering ovulation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23356536     DOI: 10.1517/14656566.2013.767334

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  20 in total

1.  Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat Study.

Authors:  T Kacan; C Yildiz; S Baloglu Kacan; M Seker; H Ozer; A Cetin
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-01       Impact factor: 2.915

2.  Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models.

Authors:  Stephen S Palmer; Melis Altan; Deborah Denis; Enrico Gillio Tos; Jean-Pierre Gotteland; Kevin G Osteen; Kaylon L Bruner-Tran; Selvaraj G Nataraja
Journal:  Reprod Sci       Date:  2015-09-02       Impact factor: 3.060

3.  Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia.

Authors:  Arrigo F G Cicero; Alessandra Reggi; Angelo Parini; Martino Morbini; Martina Rosticci; Elisa Grandi; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-04-12

4.  Impact of surgical excision of lesions on pain in a rat model of endometriosis.

Authors:  P Alvarez; L C Giudice; J D Levine
Journal:  Eur J Pain       Date:  2014-05-13       Impact factor: 3.931

5.  [Effect of GnRHa therapy following conservative laparoscopic surgery for endometriosis on clinical pregnant rate in patients with endometriosis-associated infertility].

Authors:  Li-Qing He; Xu-Zi Cai; Yan Wang; Xue-Feng Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-05-20

6.  Oxidation-sensitive nociception involved in endometriosis-associated pain.

Authors:  Kristeena Ray; Johannes Fahrmann; Brenda Mitchell; Dennis Paul; Holly King; Courtney Crain; Carla Cook; Mikhail Golovko; Stephen Brose; Svetlana Golovko; Nalini Santanam
Journal:  Pain       Date:  2015-03       Impact factor: 7.926

7.  Endometriosis: alternative methods of medical treatment.

Authors:  Leticia Muñoz-Hernando; Jose L Muñoz-Gonzalez; Laura Marqueta-Marques; Carmen Alvarez-Conejo; Álvaro Tejerizo-García; Gregorio Lopez-Gonzalez; Emilia Villegas-Muñoz; Angel Martin-Jimenez; Jesús S Jiménez-López
Journal:  Int J Womens Health       Date:  2015-06-11

Review 8.  Molecular aspects of development and regulation of endometriosis.

Authors:  Yana B Aznaurova; Marat B Zhumataev; Tiffany K Roberts; Alexander M Aliper; Alex A Zhavoronkov
Journal:  Reprod Biol Endocrinol       Date:  2014-06-13       Impact factor: 5.211

9.  Soluble ligands for the NKG2D receptor are released during endometriosis and correlate with disease severity.

Authors:  Iñaki González-Foruria; Pietro Santulli; Sandrine Chouzenoux; Francisco Carmona; Frédéric Batteux; Charles Chapron
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

10.  Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling.

Authors:  Rajesh Kumar; Anne-Catherine Clerc; Ilaria Gori; Ronan Russell; Chiara Pellegrini; Lerisa Govender; Jean-Christophe Wyss; Dela Golshayan; Geraldine O Canny
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.